JPRN-jRCT2031190020进行中（未招募）1 期
Phase I study of pevonedistat in combination with capecitabine and oxaliplatin (CapeOX) in patients with advanced gastric cancer refractory to platinum - CaPevOX-1
Shoji Hirokazu0 个研究点目标入组 23 人开始时间: 2019年5月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients who are diagnosed as having any of adenocarcinoma (pupillary adenocarcinoma, tubular adenocarcinoma, or poorly differentiated adenocarcinoma), signet-ring cell carcinoma and mucinous carcinoma.
- •2) Patients with unresectable advanced gastric cancer or those with recurrent gastric cancer (including those with carcinoma of gastroesophageal junction).
- •3) Patients whose CT images show no massive ascites toward the upper abdomen over the pelvic cavity, and patients without massive ascites requiring drainage.
- •4) Patients who can take food orally.
- •5) Patients who are 20 years old or older at the registration.
- •6) Patients with ECOG performance status (PS) of 0 or 1.
- •7) Patients in whom at least 1 measurable lesion* was proven with thoracic-abdominal-pelvic CT scan.
- •8) Patients who are refractory or intolerant to fluoropyrimidines (at least one of 5-FU, capecitabine or S-1), first-line chemotherapy containing cisplatin or oxaliplatin, or second-line chemotherapy containing taxanes for gastric cancer and have been treated with two or more regimens of anticancer therapy previously.
- •9) Peripheral sensory neuropathy and peripheral motor neuropathy
- •less than Grade 1 defined by CTCAE v5.0
- •10) Patients who were not treated with systemic antineoplastic therapy (including investigational drugs) within 14 days before the registration.
- •11) Patients who were not radiated to their spinal cord or pelvis within 28 days before the registration, and those who did not receive radiation to the organs other than the spinal cord and pelvis within 14 days before the registration.
- •12) Patient whose clinical laboratory test values obtained within 3 days before the registration meet the following criteria.
- •13) Female patients who agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug or 6 months after the last dose of capecitabine, whichever comes later.
- •14) Male patients, even if surgically sterilized (ie, status postvasectomy), who agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug or 3 months after the last dose of capecitabine, whichever comes later.
- •15) Patients who have provided a written informed consent to participate in the trial.
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancies except for carcinoma in situ or mucosal tumors curatively treated with local therapy.
- •2) Patients with an infectious disease requiring systemic treatment.
- •3) Intorelant to capecitabine and/or oxaliplatin.
- •4) Prothrombin time (PT) or activated partial thromboplastin time (APTT) exceeds 1.5 times the institution standard value or has poorly controlled active coagulopathy or hemorrhagic disease
- •5) Known cardiopulmonary disease.
- •6) Left ventricular ejection fraction (LVEF) measured using echocardiography (ECHO), less than 50%
- •7) Major surgery or laparotomized biopsy under general anesthesia within 14 days prior to registration
- •8) Metastasis to the central nervous system (brain, spinal cord, meningeal) is evident
- •9) Patients with Liver cirrhosis or severe hepatic disorder
- •10) Have a life-threatening disease not related to gastric cancer
- •11) A positive test result for any of the followings: Human immunodeficiency virus antibody, hepatitis B surfaces (HBs) antigen, or hepatitis C virus antibody.
- •12) Positive test result for either HBs antibody or hepatitis B core antibody, with a detectable level of hepatitis B virus-deoxyribonucleic acid (HBV-DNA) even in case of negative HBs antigen test
- •13) Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.
- •14) Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s) or 6 months following the last dose of capecitabine, whichever comes later.
- •15) Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s) or 3 months following the last dose of capecitabine, whichever comes later.
- •16) Judged to be incapable of providing consent for certain reasons, such as concurrent dementia
- •17) Require or have received systemic corticosteroids or immunosuppressants
- •18) Uncontrolled high blood pressure (ie, systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg).
- •19) Prolonged rate corrected QT (QTc) interval more than 500 msec, calculated according to institutional guidelines.
- •20) Known moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary fibrosis.
- •21) Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures.
研究者
相似试验
已完成
1 期
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or LymphomaRecurrent LymphomaRecurrent Malignant Solid NeoplasmRecurrent Primary Central Nervous System NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Primary Central Nervous System NeoplasmNCT03323034Children's Oncology Group30
暂停
2 期
Phase II study of pevonedistat plus niraparib in patient with recurrent ovarian cancerovarian cancerJPRN-jRCT2031210181Hasegawa Kosei33
进行中（未招募）
1 期
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaB-Cell Prolymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Lymphoplasmacytic LymphomaRefractory Mantle Cell LymphomaRefractory Marginal Zone LymphomaRefractory Non-Hodgkin LymphomaRefractory Small Lymphocytic LymphomaRichter SyndromeNCT03479268City of Hope Medical Center18
终止
1 期
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid TumorLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmNCT04800627M.D. Anderson Cancer Center2
已完成
1 期
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT03009240City of Hope Medical Center12